Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with Pembrolizumab in Patients with Metastatic or Locally Advanced Colorectal or Gastric Cancer/ Gastroesophageal Junction Adenocarcinoma

NCT03724851 is registered in ClinicalTrials.gov with MedPacto, Inc. as lead sponsor.

NCT NCT03724851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03724851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with Pembrolizumab in Patients with Metastatic or Locally Advanced Colorectal or Gastric Cancer/ Gastroesophageal Junction Adenocarcinoma
Lead sponsor
MedPacto, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 20, 2018
Completion date
May 7, 2024
Enrollment
120 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction adenocarcinoma, metastatic colorectal cancer